首页> 中文期刊> 《中国医药导报》 >急性重症胰腺炎早期容量治疗的临床观察

急性重症胰腺炎早期容量治疗的临床观察

         

摘要

Objective To improve the severe acute pancreatitis understanding,and observe clinical efficacy and safety on capacity treatment for severe acute pancreatitis.Methods 80 cases of acute pancreatitis patients were randomly divided into observation group of 40 cases and control group of 40 cases,control group was given Regular Crystal Fluid Physiological Saline Injection capacity support,the treatment group was given the Conventional Crystal Fluid Physiological Saline Injection combined with Hydroxyethyl Starch Injection capacity support.Results Systemic inflammatory response syndrome,bowel sound recovery time,blood amylase restore normal time,C-reactive protein duration,the average hospitalization time of treatment group were shorter than that in control group (P < 0.05),the treatment group's total effective rate was significantly higher than that in control group (P < 0.05),the treatment group's complication rates significantly lower than that in control group (P < 0.05).Conclusion Severe acute pancreatitis acute reaction period should be early line capacity support,curative effect is reliable,and can reduce the complications.%目的 提高对重症急性胰腺炎的认识,观察容量治疗重症胰腺炎的临床疗效和安全性.方法 将80例急性胰腺炎患者随机分为观察组40例和对照组40例,对照组给予常规晶体液生理盐水注射液容量支持,治疗组在常规晶体液生理盐水注射液联合羟乙基淀粉注射液容量支持.观察两组治疗前后临床指标的变化.结果 治疗组的全身炎症反应综合征、肠鸣音恢复时间、血淀粉酶恢复正常时间、C-反应蛋白持续时间、平均住院时间均短于对照组(P<0.05),治疗组的总有效率显著高于对照组(P<0.05),治疗组的并发症发生率显著低于对照组(P<0.05).结论 重症急性胰腺炎急性反应期宜早期行容量支持,疗效可靠,并能减少并发症.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号